Marc G Vervloet
Overview
Explore the profile of Marc G Vervloet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
2783
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zoccali C, Vervloet M, Evenepoel P, Massy Z, Cozzolino M, Mallamaci F, et al.
Clin J Am Soc Nephrol
. 2025 Mar;
PMID: 40085147
No abstract available.
2.
Bakker W, Heerspink H, Berger S, Wanner C, Badve S, Arnott C, et al.
Nephrol Dial Transplant
. 2025 Mar;
PMID: 40053493
Background: Several clinical trials have shown beneficial effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on kidney disease progression and cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD)...
3.
Zoccali C, Vervloet M, Evenepoel P, Massy Z, Cozzolino M, Mallamaci F, et al.
Eur J Clin Invest
. 2025 Feb;
:e70007.
PMID: 39985733
Besides the well-known role of hormonal factors in mineral and bone metabolism, the sympathetic nervous system participates in this regulation by inhibiting bone formation and promoting bone resorption, primarily via...
4.
Ketteler M, Evenepoel P, Holden R, Isakova T, Jorgensen H, Komaba H, et al.
Kidney Int
. 2025 Jan;
107(3):405-423.
PMID: 39864017
In 2017, Kidney Disease: Improving Global Outcomes (KDIGO) published a Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Since...
5.
Kane J, Vos W, Bosmans L, van Os B, den Toom M, Hoeksema-Hackmann S, et al.
J Am Heart Assoc
. 2024 Jul;
13(14):e034066.
PMID: 38979792
Background: Atherosclerosis is highly prevalent in people with chronic kidney disease (CKD), including those receiving peritoneal dialysis (PD). Although it is lifesaving, PD induces profound systemic inflammation, which may aggravate...
6.
Vervloet M, Smulders Y
Ned Tijdschr Geneeskd
. 2024 Jun;
168.
PMID: 38888413
Almost all laboratories in The Netherlands report an estimated glomerular filtration rate (eGFR) whenever a value for plasma creatinine is requested. This formula is based on gender and age, besides...
7.
Vervloet M, de Jong H, Pander J, Overbeek J
BMC Nephrol
. 2023 Nov;
24(1):337.
PMID: 37957561
Background: Knowledge on prevalence, comorbidities and consequences of chronic kidney disease (CKD) is mandatory to estimate the potential of cardiovascular risk management on a population level. We studied the prevalence...
8.
Vervloet M
Clin Kidney J
. 2023 Nov;
16(11):1766-1775.
PMID: 37915898
The increased cardiovascular risk of chronic kidney disease may in part be the consequence of arterial stiffness, a typical feature of kidney failure. Deranged homeostasis of minerals and hormones involved...
9.
Hsu S, Vervloet M, de Boer I
Am J Kidney Dis
. 2023 Sep;
82(5):512-514.
PMID: 37715768
No abstract available.
10.
Vervloet M, Hsu S, de Boer I
Kidney Int
. 2023 Aug;
104(4):698-706.
PMID: 37541585
Vitamin D supplements have long been advocated for people with chronic kidney disease based on data from observational studies among the general population and people with chronic kidney disease. These...